JPMorgan Chase Financial Co. LLC has filed a pricing supplement for $1 million in auto callable contingent interest notes linked to the common stock of Pfizer Inc. This move is significant as it showcases JPMorgan's strategy in structured investments within the national commercial banking sector.

The notes are designed for investors who seek contingent interest payments based on the performance of Pfizer's stock. If the stock price meets certain conditions, investors may receive interest payments, but they also face the risk of losing principal if the stock performs poorly.

Background

JPMorgan Chase Financial Co. LLC, part of JPMorgan Chase & Co., operates primarily in the national commercial banks sector, classified under SIC 6021. The company is incorporated in Delaware and has its business address at 383 Madison Avenue, New York, NY. The latest filing, dated November 6, 2026, falls under the 424B2 form type, indicating a registration for securities offerings.

What the Filing Says

The filing outlines the terms of the structured notes, which are fully guaranteed by JPMorgan Chase & Co. The notes offer a contingent interest payment if the stock price of Pfizer meets specified thresholds. The filing states, "The notes are unsecured and unsubordinated obligations of JPMorgan Chase Financial Company LLC, which we refer to as JPMorgan Financial, the payment on which is fully and unconditionally guaranteed by JPMorgan Chase & Co."

Impact

This offering may affect a range of investors looking for innovative investment products linked to established companies like Pfizer. It highlights JPMorgan's commitment to providing structured investment opportunities, which could influence competitors to enhance their own offerings in the structured investment space.

What's Next

Details were not available in the SEC filing regarding any subsequent actions or future filings related to this offering.